Skip to main content
. 2024 Mar 13;13(5):e7025. doi: 10.1002/cam4.7025

FIGURE 4.

FIGURE 4

Comparison of overall survival (OS) and progression‐free survival (PFS) from the start of atezolizumab plus bevacizumab (Atezo + Beva) between patients without portal hypertension (PH(−)) and with portal hypertension (PH(+)) after propensity score matching. (A) OS from the start of Atezo + Beva (PH(−) 18.4 months, PH(+) 18.8 months, p = 0.71). (B) PFS from the start of Atezo + Beva (PH(−) 8.6 months, PH(+) 5.8 months, p = 0.92).